Acute psychological effects of 3, 4-methylenedioxymethamphetamine (MDMA,“Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram

3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") is an amphetamine derivative known from controlled studies to produce a characteristic psychoactive profile in humans, including heightened mood, increased sociability, moderate derealization and depersonalization, cognitive disturbances, and intensified sensory awareness. Preclinical work shows that MDMA primarily releases serotonin (5-HT) and, to a lesser extent, dopamine (DA), and that selective serotonin reuptake inhibitors (SSRIs) such as citalopram block MDMA-induced 5-HT release in vitro and in animals, suggesting carrier-mediated 5-HT efflux as a mechanism. It remains unclear, however, whether this mechanism accounts for MDMA's psychological effects in humans, as prior human information consisted mainly of uncontrolled case reports with mixed findings. Liechti and colleagues set out to test whether acute pretreatment with the highly selective 5-HT uptake inhibitor citalopram would attenuate the psychological effects of orally administered MDMA in healthy volunteers. The study used psychometric rating scales in a double-blind, placebo-controlled within-subject design and hypothesised that a 40 mg intravenous infusion of citalopram would reduce the subjective effects produced by 1.5 mg/kg oral MDMA.

The investigators conducted a double-blind, placebo-controlled, within-subject experiment with 16 healthy volunteers (12 male, 4 female), aged 21–39 years (mean 27.4 ± 4.4). Each participant completed four experimental sessions in counterbalanced order: placebo-placebo, citalopram-placebo, placebo-MDMA, and citalopram-MDMA, with at least 14 days between sessions to avoid carry-over effects. Exclusion criteria included personal or first-degree family history of major psychiatric disorder, head injury, regular substance or alcohol abuse, and elevated neuroticism scores on the Freiburger Personality Inventory. Six participants had prior recreational drug experience (two had tried Ecstasy). Citalopram hydrochloride 40 mg was administered intravenously, dissolved in 500 ml saline and infused over 90 minutes (≈330 ml/h). Racemic MDMA hydrochloride was given orally at 1.5 mg/kg (mean dose 100 mg ± 10), encapsulated. The timing was such that the IV infusion finished before oral administration; psychometric assessments were performed 120 minutes after MDMA/placebo intake (about 75 minutes after the expected onset of subjective effects). Cardiovascular measures and body temperature were monitored throughout; adverse effects were assessed during the session and at one and three days afterward. Subjective effects were assessed with two validated instruments. The Adjective Mood Rating Scale (AM) measures 14 mood-related scales including heightened mood, self-confidence, extroversion, and others. The Altered States of Consciousness Rating Scale (ASC) is a 66-item visual-analog instrument with three principal scales: Oceanic Boundlessness (OB; derealization/depersonalization and positive mood), Anxious Ego Dissolution (AED; ego-disintegration and anxiety-related items), and Visionary Restructuralization (VR; perceptual changes and imagery). Statistical analyses involved checking distributions with Kolmogorov-Smirnov tests. The ASC effects of MDMA versus placebo were first assessed by MANOVA. To test for a specific inhibiting effect of citalopram on MDMA-induced changes, the team used two-way repeated-measures ANOVA with pretreatment (placebo vs citalopram) and treatment (placebo vs MDMA) as within-subject factors; Tukey post hoc tests examined subscore differences. AM scale scores were analysed with nonparametric Wilcoxon matched-pairs tests due to discrete, non-normally distributed data. Significance was set at p < .05.

All 16 participants completed the study. Oral MDMA at 1.5 mg/kg produced a predominantly positive affective state with heightened mood, increased self-confidence and extroversion, moderate derealization/depersonalization, intensified sensory awareness, and a slight rise in psychomotor drive. Subjective effects typically began between 20 and 120 minutes after ingestion (mean onset 45 minutes), peaked 15–30 minutes later, and lasted on average about 3 hours under MDMA alone. When participants were pretreated with citalopram, the peak subjective effects were markedly reduced but the mean duration was prolonged to approximately 5 hours. On the ASC, MDMA significantly elevated all three main scales compared to placebo (MANOVA: Rao R(3,12) = 7.25; p < .005), with highly significant increases on OB (p < .0004), AED (p < .0005) and VR (p < .007). Item-cluster analyses showed that OB increases were driven by "positive basic mood" (p < .0002), "derealization" (p < .0002), and "alterations of the sense of time" (p < .0005), with moderate increases in "mania-like experience" and "depersonalization". AED increases included "thought disorder" (p < .0001) and smaller effects on "frightening derealization" (p < .01), "loss of thought control" (p < .002), and "loss of body control" (p < .0002). VR increases were prominent for "changed meaning of percepts" (p < .0002), with moderate elevations in "facilitated recollection" and "facilitated imagination" (both p < .002) and a smaller rise in "synesthesia" (p < .01). Two-way ANOVAs revealed significant pretreatment-by-treatment interactions for all three ASC scales, confirming that citalopram reduced MDMA's psychological effects: OB F(1,15) = 22.47, p < .0003; AED F(1,15) = 23.04, p < .0002; VR F(1,15) = 12.80, p < .027. Citalopram attenuated MDMA-induced increases across most item clusters, with significant reductions in "positive mood" (p < .0003), "mania-like experience" (p < .0003), "derealization" and "depersonalization" (p < .007), "alterations of the sense of time" (p < .03), "thought disorder" (p < .0003), "loss of thought-control" (p < .01), "loss of body control" (p < .006), "changed meaning of percepts" (p < .0002), and "facilitated imagination" (p < .01). The decrease for "frightening derealization" did not reach significance (p ≈ .06). On the AM mood scales, MDMA increased "heightened mood" (p < .03), "self-confidence" (p < .02), "extroversion" (p < .01), and unexpectedly also "introversion" (p < .05), along with "emotional excitability" (p < .01), "sensitivity" (p < .03) and "thoughtfulness-contemplativeness" (p < .002). MDMA reduced "tiredness" (p < .05) and increased "dazed state" (p < .02), while leaving "aggression-anger", "apprehension-anxiety", and "depressiveness" unchanged. Citalopram pretreatment significantly reduced MDMA-induced increases in "self-confidence" (p < .04) and "extroversion" (p < .01) to levels comparable with citalopram alone; "efficiency-activation" under MDMA was also reduced by citalopram (p < .03). Several other MDMA-induced score changes trended toward reversal with citalopram, but increases in "emotional excitability" and "sensitivity" were not attenuated. The authors report that citalopram reduced the MDMA psychological profile by roughly 60% on average. Cardiovascular and startle-measure effects were assessed but reported separately; the extracted text does note that citalopram produced side effects such as nausea in some subjects (mentioned as 6/16 in the Discussion) and that citalopram alone affected some mood scales.

Liechti and colleagues interpret the findings as supporting a primary role for carrier-mediated 5-HT release in MDMA's acute psychological effects. MDMA produced an entactogen-like profile—enhanced mood, increased sociability and self-confidence, moderate derealization/depersonalization, thought disorder without frank psychosis, and intensified sensory perception—but these effects were substantially attenuated by pretreatment with the selective serotonin uptake inhibitor citalopram. The authors argue that this attenuation is consistent with preclinical data showing that SSRIs block MDMA-induced 5-HT release, and that citalopram's high selectivity for the 5-HT transporter makes an interaction at that site the most plausible explanation. At the same time, the investigators acknowledge that citalopram only reduced MDMA effects by about 60%, indicating additional mechanisms beyond 5-HT release. They discuss possible contributors including direct actions at postsynaptic 5-HT2A/2C receptors, DA and norepinephrine (NE) release and receptor-mediated effects, and MDMA affinity for several receptor types. The persistence of MDMA-induced "emotional excitability" and "sensitivity" despite citalopram pretreatment is offered as potential evidence for DA or NE involvement. The authors further note that MDMA's ability to alter perception may involve 5-HT2 receptor activation and that MDMA stimulates DA release in striatum, which may be amplified by 5-HT-mediated mechanisms. Methodological and interpretative caveats are acknowledged. Nonspecific side effects of citalopram, such as fatigue, headache and nausea, could have reduced some pleasurable aspects of the MDMA experience, although the investigators consider it unlikely that these effects alone account for the broad attenuation observed. The prolongation of subjective MDMA effects with citalopram pretreatment (from about 3 to 5 hours) is discussed; possible explanations include metabolic interactions via CYP2D6 inhibition by citalopram, delayed 5-HT efflux because of transporter competition, or transporter regulatory effects such as phosphorylation/sequestration. The authors also compare their controlled findings with a small retrospective case series that reported minimal change when fluoxetine preceded Ecstasy, suggesting differences in SSRI dose, SSRI identity, MDMA dose and the uncontrolled nature of the prior reports likely explain the discrepancy. Finally, the study's implications for future research are outlined. The authors conclude that human pharmacological challenge studies with MDMA and selective receptor ligands can help clarify the neurochemical substrates of mood regulation and the role of serotonergic and other systems in affective processes. They recommend further investigations using specific receptor antagonists/agonists to dissect the contributions of postsynaptic 5-HT2, DA and NE receptors to MDMA's psychological effects.